Neurocrine Biosciences

At a glance

Neurocrine Biosciences reported 2025 revenue of $2.86B, up 21.4% from $2.36B in 2024. Over 4 years since 2021 ($1.13B), that is growth of about 26% a year. Operating margin was 21.6%, up from 9% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 15 insiders reported 0 open-market purchases and 26 sales ($77.9M). 25 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $37.8M by Director Kevin Charles Gorman on May 21, 2026.

Neurocrine Biosciences filed 9 current reports (Form 8-K) in the last 12 months, most often for officer or director change (3), results of operations (3), material agreement (2) and exhibits (1). The latest officer or director change was reported on Sep 28, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.

3 of the 20 investors tracked here held Neurocrine Biosciences at the last quarter end, worth $431.1M combined. It is the largest weight for Renaissance Technologies (0.5% of its portfolio), followed by Bridgewater Associates (0.1%). Added: Bridgewater Associates. Reduced: Renaissance Technologies and National Pension Service (Korea).

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.